Literature DB >> 8662591

Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation.

C Gerhartz1, B Heesel, J Sasse, U Hemmann, C Landgraf, J Schneider-Mergener, F Horn, P C Heinrich, L Graeve.   

Abstract

Interleukin-6 (IL-6) and gamma-interferon (IFNgamma) activate an overlapping set of genes via the Jak/STAT pathway. However, at least in human cells, a differential activation of STAT transcription factors was observed: IL-6 activates both acute phase response factor (APRF)/STAT3 and STAT1, whereas IFNgamma leads only to STAT1 activation. All STATs cloned so far contain SH2 domains. Since all cytokine receptors using the Jak/STAT pathway were found to be tyrosine-phosphorylated after ligand binding, it has been proposed that specific phosphotyrosine modules within the cytoplasmic domain of the receptor chains recruit different STAT factors. We have analyzed by mutational studies and by phosphopeptide competition assays which of the tyrosine modules of the IL-6 signal transducer gp130 are capable of recruiting either APRF or STAT1. We found that two of the four tyrosine modules that are important for APRF activation also activate STAT1. For these modules, we propose the new consensus sequence YXPQ. We further present evidence that STAT1 is activated independently from APRF suggesting that gp130 contains multiple independent STAT binding sites. We compare the APRF and STAT1 activation motifs of gp130 with the STAT1 activation motif of the IFNgamma receptor and demonstrate that the specificity of activation can be changed from APRF to STAT1 and vice versa by only two point mutations within a tyrosine module. These data strongly support the concept that the activation of a specific STAT is determined mainly by the phosphotyrosine module. The significance of these findings for other receptor systems is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662591     DOI: 10.1074/jbc.271.22.12991

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Cytoplasmic STAT proteins associate prior to activation.

Authors:  S Haan; M Kortylewski; I Behrmann; W Müller-Esterl; P C Heinrich; F Schaper
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

Review 2.  Interleukin 6 and liver regeneration.

Authors:  K L Streetz; T Luedde; M P Manns; C Trautwein
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

Review 3.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

4.  Solid-phase synthesis of Stat3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics.

Authors:  Pijus K Mandal; Patricia A Heard; Zhiyong Ren; Xiaomin Chen; John S McMurray
Journal:  Bioorg Med Chem Lett       Date:  2006-11-06       Impact factor: 2.823

5.  Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells.

Authors:  Antje K Kretzschmar; Michaela C Dinger; Christian Henze; Katja Brocke-Heidrich; Friedemann Horn
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

Review 6.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

Review 7.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

8.  Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease.

Authors:  S Schreiber; P Rosenstiel; J Hampe; S Nikolaus; B Groessner; A Schottelius; T Kühbacher; J Hämling; U R Fölsch; D Seegert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.

Authors:  F Schaper; C Gendo; M Eck; J Schmitz; C Grimm; D Anhuf; I M Kerr; P C Heinrich
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

10.  Role of STAT3 and GATA-1 interactions in gamma-globin gene expression.

Authors:  Xiao Yao; Sirisha Kodeboyina; Li Liu; James Dzandu; Jose Sangerman; Solomon F Ofori-Acquah; Betty S Pace
Journal:  Exp Hematol       Date:  2009-05-15       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.